U.S. Supreme Court to Hear Oral Arguments April 29 in Hikma v. Amarin — Skinny Label and Induced Infringement Standard at Stake

The U.S. Supreme Court is scheduled to hear oral arguments on April 29, 2026, in Hikma Pharmaceuticals USA Inc. v. Amarin Pharma, Inc. (No. 24-889), a patent case that will determine how far a branded drug maker can reach beyond a generic’s label to allege induced infringement. The parties filed their merits briefs on April 21, setting the stage for an argument that carries substantial implications for the U.S. generic drug market and Hatch-Waxman litigation practice.

Background: Vascepa and the Skinny Label

At the center of the dispute is Amarin’s cardiovascular drug Vascepa® (icosapent ethyl), approved by the FDA for two indications: (1) treatment of severe hypertriglyceridemia—an off-patent use—and (2) reduction of cardiovascular risk in high-risk patients, a use still covered by active patents. Hikma sought FDA approval for a generic version using a “skinny label,” formally carving out the patented cardiovascular indication under the statutory framework available under the Hatch-Waxman Act. The carve-out process is a recognized, Congress-endorsed mechanism for enabling generic competition on off-patent uses while preserving brand exclusivity on patented indications.

Amarin filed suit in 2020, alleging that despite the carved-out label, Hikma’s public communications—specifically press releases describing its product as “a generic version of Amarin Corporation’s Vascepa®”—effectively directed physicians toward the patented cardiovascular use, constituting induced infringement under 35 U.S.C. § 271(b).

Lower Courts and the Path to SCOTUS

The District of Delaware initially dismissed Amarin’s complaint, finding that the alleged conduct did not plausibly establish active inducement. The U.S. Court of Appeals for the Federal Circuit reversed in 2024, holding that when viewed holistically—combining the skinny label content and Hikma’s external marketing materials—Amarin’s allegations were sufficient to survive a motion to dismiss.

The Supreme Court granted certiorari on January 16, 2026, agreeing to resolve two questions: (1) whether describing a product as a “generic version” of the branded drug and citing publicly available sales figures constitutes plausible inducement of the patented use, when the generic label fully carves out that use; and (2) whether a complaint can state a claim for induced infringement without alleging any statement by the defendant that encourages—or even mentions—the patented use.

Competing Arguments

Hikma’s opening brief argues that a generic manufacturer that dutifully carves out a patented indication cannot face induced infringement liability merely for identifying its product as a “generic” of the branded drug. Generics are, by their nature, therapeutically equivalent to branded drugs across their shared indications—a fact that does not disappear because one use is carved out. To hold otherwise, Hikma contends, would effectively nullify the Hatch-Waxman Act’s skinny label mechanism and chill generic competition that Congress explicitly intended to promote.

Amarin counters that Hikma’s conduct went beyond neutral product description. By explicitly branding its drug as “Hikma’s generic version of Vascepa®”—without distinguishing which therapeutic uses were covered—Hikma communicated to prescribers that its product was a full substitute, including for the patented cardiovascular use. The Federal Circuit’s totality-of-the-circumstances approach, Amarin argues, correctly captures the real-world impact of such communications on prescribing patterns.

The Solicitor General was granted divided argument time on March 24, 2026, signaling the U.S. government’s significant interest in the outcome. The government’s position—expected to articulate a framework defining when non-label communications can support an inducement claim—may prove influential in shaping the Court’s reasoning.

What’s at Stake

The skinny label mechanism is one of the Hatch-Waxman framework’s most commercially significant tools, enabling generic entry on off-patent indications while preserving brand patent protection on newer uses. Its practical effect on drug pricing and patient access has made it a focal point for both the generic pharmaceutical industry and branded drug manufacturers.

If the Supreme Court endorses the Federal Circuit’s holistic approach, generic manufacturers will face heightened legal exposure for routine product communications, effectively forcing a choice between launching under a skinny label and maintaining silence on brand-comparison messaging. Critics warn this could chill generic competition and extend branded drug market exclusivity beyond what Congress intended.

Conversely, if the Court narrows inducement liability to the four corners of the label, branded manufacturers will need to rely on other mechanisms—including method-of-treatment patents and risk evaluation and mitigation strategies (REMS)—to protect patented indications from off-label substitution driven by physician prescribing patterns.

Oral arguments are set for April 29, 2026. A decision is expected before the end of the Court’s October 2025 term, likely in late June or early July 2026.